Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides.

Front Immunol · 2026 · PMC13275460 · PMID 42327725

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

claims-based cohort published in 2024, TNF inhibitors served as the reference category and were associated with lower incident cancer rates than rituximab and abatacept, while differences versus JAK inhibitors did not reach statistical significance within two years of follow-up ( 24 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.